natgillin/translations-raw huggingface dataset:
repaglinid, pioglitazon, nateglinid nebo rosiglitazon na cukrovku
repaglinide, pioglitazone, nateglinide, or rosiglitazone for diabetes
Repaglinid, podobně jako jiné látky stimulující sekreci inzulínu, může způsobit hypoglykémii.
Repaglinide, like other insulin secretagogues, is capable of producing hypoglycaemia.
Repaglinid: AUC: ↑ 1,2krát
Repaglinide: AUC: ↑ 1.2-fold
Repaglinid: AUCinf: ↓ 8%
AUCinf: ↓ 8
Repaglinid: AUCinf: ↓ 8%
Repaglinide: AUCinf: ↓ 8
Repaglinide Accord 0,5 mg tablety
Repaglinide Accord 0.5 mg tablets
Repaglinide Accord 0,5 mg tablety jsou bílé až téměř bílé, kulaté, bikonvexní se zkosenými hranami a označením „R“ na jedné straně a hladké na druhé straně.
The Repaglinide Accord 0.5 mg tablet is white to off white, round, biconvex, with beveled edge, with inscription ‘R’ on one side and plain on other side.
Repaglinide Accord 0,5 mg tablety Repaglinidum
Repaglinide Accord 0.5 mg tablets Repaglinide
Repaglinide Accord 1 mg tablety
Repaglinide Accord 1 mg tablets
Repaglinide Accord 1 mg tablety Repaglinidum
Repaglinide Accord 1 mg tablets Repaglinide
Repaglinide Accord 2 mg tablety
Repaglinide Accord 2 mg tablets
Repaglinide Accord 2 mg tablety Repaglinidum
Repaglinide Accord 2 mg tablets Repaglinide
Repaglinide Accord repaglinidum
Repaglinide Accord repaglinide
Repaglinide Krka 0,5 mg tablety Repaglinidum
Repaglinide Krka 0.5 mg tablets Repaglinide
Repaglinide Krka 1 mg tablety Repaglinidum
Repaglinide Krka 1 mg tablets Repaglinide
Repaglinide Krka 2 mg tablety Repaglinidum
Repaglinide Krka 2 mg tablets Repaglinide
Repaglinide Krka nesmíte užívat, jste-li těhotná nebo těhotenství plánujete.
You should not take Repaglinide Krka if you are pregnant or you are planning to become pregnant.
Repaglinide Teva repaglinide
EMEA/H/C/ 1067
Reparace jednotlivých symptomatických lézí chrupavky femorálního kondylu kolene (stupeň III nebo IV dle ICRS [International Cartilage Repair Society – Mezinárodní společnost pro reparaci/obnovu chrupavky]) u dospělých.
Repair of single symptomatic cartilage defects of the femoral condyle of the knee (International Cartilage Repair Society [ICRS] grade III or IV) in adults.
Repatha 140 injekční stříkačka
Repatha 140 syringe
Repatha 140 mg injekce evolocumabum s.c.
Repatha 140 mg injection evolocumab
Repatha 140 mg injekční roztok evolocumabum
Repatha 140 mg solution for injection evolocumab
Repatha 140 mg injekční roztok v předplněné injekční stříkačce
Repatha 140 mg solution for injection in pre-filled syringe
Repatha 140 mg injekční roztok v předplněném peru
Repatha 140 mg solution for injection in pre-filled pen
Repatha 140 pero
Repatha 140 pen
Repatha evolocumabum
Repatha evolocumab
Repatha je lidská monoklonální protilátka IgG2 produkovaná buňkami ovarií čínských křečků (CHO) pomocí technologie rekombinantní DNA.
Repatha is a human IgG2 monoclonal antibody produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells.
Repatha je léčivý přípravek používaný k léčbě:
Repatha is a medicine used to treat:
Repatha předplněná injekční stříkačka na jedno použití
Repatha single use pre-filled syringe
Repatha SureClick předplněné pero na jedno použití
Repatha single use SureClick pre-filled pen
Replagal 1 mg/ml koncentrát pro infuzní roztok Agalsidasum alfa
Replagal 1 mg/ml concentrate for solution for infusion agalsidase alfa
Replagal 1 mg/ml koncentrát pro infuzní roztok.
Replagal 1 mg/ml concentrate for solution for infusion.
Replagal 1 mg/ml koncentrát pro infúzní roztok
Replagal 1 mg/ml concentrate for solution for infusion
Replagal 1 mg/ml sterilní koncentrát Agalsidasum alfa
Replagal 1 mg/ml sterile concentrate agalsidase alfa
Replagal je indikován k dlouhodobé enzymatické substituční terapii u pacientů s potvrzenou diagnózou Fabryho nemoci (deficience -galaktosidázy A).
Replagal is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency).
Replagal neaplikujte stejným infúzním setem společně s jinými látkami.
Do not infuse Replagal concomitantly in the same intravenous line with other agents.
Replagal se nemá podávat společně s chlorochinem, amiodaronem, benochinem či gentamycinem, protože tyto látky mohou potenciálně tlumit nitrobuněčnou aktivitu -galaktosidázy.
Replagal should not be co-administered with chloroquine, amiodarone, benoquin or gentamicin since these substances have the potential to inhibit intra-cellular α-galactosidase activity.
Replagal se podává každý druhý týden v dávce 0,2 mg/kg tělesné hmotnosti intravenózní infúzí po dobu 40 minut.
Replagal is administered at a dose of 0.2 mg/kg body weight every other week by intravenous infusion over 40 minutes.
Replikony HCV exprimující substituci v S282T související s rezistencí na sofosbuvir byly plně citlivé na jiné třídy léků proti HCV.
HCV replicons expressing the sofosbuvir-associated resistance substitution S282T were fully susceptible to other classes of anti-HCV agents.
Replikony s jednou substitucí na pozici 155 nebo 156 a dvojité varianty se substitucí na reziduech 36 a 155 vykázaly zkříženou rezistenci ke všem testovaným inhibitorům proteázy v širokém rozsahu citlivostí.
Replicons with single substitutions at position 155 or 156 and double variants with substitutions at residues 36 and 155 showed cross-resistance to all protease inhibitors tested with a wide range of sensitivities.
Reprezentují hodnocení údajů o nežádoucích účincích od 870 pacientů s nově diagnostikovanou Ph+ CML v chronické fázi nebo s Ph+ CML v chronické, akcelerované nebo blastické fázi nebo s Ph+ akutní lymfoblastickou leukemií (ALL), kteří byli rezistentní nebo netolerovali předchozí léčbu a kteří užili alespoň 1 dávku bosutinibu samotného.
These represent an evaluation of the adverse reaction data from 870 patients with newly diagnosed Ph+ chronic phase CML or with Ph+ chronic, accelerated, or blast phase CML or Ph+ acute lymphoblastic leukaemia (ALL) resistant or intolerant to prior therapy and who have received at least 1 dose of single-agent bosutinib.
Reproduction is authorised provided the source is acknowledged vylučování viru výkaly a nosním sekretem.
Reproduction is authorised provided the source is acknowledged monitored included weight gain, mortality as well as faecal and nasal shedding.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. amount of food or drink immediately before swallowing it.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. are stable, and then periodically.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. around 4 hours.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. considered more appropriate.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. consult their doctor.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. dose of 100 mg twice a day.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. dummy treatment).
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. edoxaban from the body.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. levels of amprenavir in the blood.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. minutes.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. necessary depending on the patient’s response.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. people have no immunity (protection) against it.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. problems treatment should be interrupted.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. recommended one month after the initial treatment.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. worse or side effects become unacceptable.
Reproduction is authorised provided the source is acknowledged. a nemohou jim být transplantovány hematopoetické (krvetvorné) kmenové buňky nebo kteří na tuto léčbu nereagovali.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. a toxemie (syndrom mastitida-metritida-agalakcie).
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. a v případě potřeby může být zastřižen na požadovanou velikost.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. aby se glukóza dostávala z krve do buněk.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. adenokarcinom žaludku (typ karcinomu žaludku) u pacientů s karcinomem, kterým zatím nebyla poskytnuta žádná léčba.
Reproduction is authorised provided the source is acknowledged. gastric adenocarcinoma (a type of stomach cancer) in patients who have not yet received any treatment for their cancer.
Reproduction is authorised provided the source is acknowledged. adenokarcinom žaludku (typ karcinomu žaludku) u pacientů, kterým v souvislosti s jejich karcinomem nebyla zatím poskytnuta žádná léčba.
Reproduction is authorised provided the source is acknowledged. gastric adenocarcinoma (a type of stomach cancer) in patients who have not yet received any treatment for their cancer.
Reproduction is authorised provided the source is acknowledged. akutní myeloidní leukemií, přičemž kostní dřeň obsahuje více než 30 % abnormálních buněk.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. antigenů“ (proteinů na zevní membráně viru) viru nazývaného A (H1N1)v 2009.
Reproduction is authorised provided the source is acknowledged. on the outer membrane of the virus) of a virus called A(H1N1)v 2009.
Reproduction is authorised provided the source is acknowledged. antimalarika, která hubí parazita P. falciparum.
Reproduction is authorised provided the source is acknowledged. bisquinolone.
Reproduction is authorised provided the source is acknowledged. až 12 mg jednou denně.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. bazálního inzulinu snížil.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. bez léčby.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. blokádu vápníkových kanálů.
Reproduction is authorised provided the source is acknowledged. effect on calcium channels.
Reproduction is authorised provided the source is acknowledged. buněk, což vede k nekontrolované aktivitě centrálního nervového systému a smrti těchto parazitů.
Reproduction is authorised provided the source is acknowledged. which results in uncontrolled activity of the central nervous system and death of these parasites.
Reproduction is authorised provided the source is acknowledged. buňky jsou součástí imunitního systému těla a jsou aktivovány interleukinem-2, signální bílkovinou v těle.
Reproduction is authorised provided the source is acknowledged. attacking and damaging nerve cells.
Reproduction is authorised provided the source is acknowledged. buňkách řady orgánů, včetně dýchacích cest uvnitř plic.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. běžného výskytu spalniček.
Reproduction is authorised provided the source is acknowledged. measles is common.
Reproduction is authorised provided the source is acknowledged. chřipkového viru.
Reproduction is authorised provided the source is acknowledged. virus.
Reproduction is authorised provided the source is acknowledged. což by mělo být nejdříve 30 minut po užití tablety.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. cyklus blech tím, že vede k produkci sterilních vajíček a blokuje vývoj mladých stadií blech v dospělé jedince.
Reproduction is authorised provided the source is acknowledged. cycle by causing production of infertile eggs as well as by blocking the development of juvenile flea stages into adults.
Reproduction is authorised provided the source is acknowledged. daného pacienta, na rozsahu a místě krvácení a na věku a zdraví pacienta.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. denně.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. dlouho, dokud to lékař považuje za přínosné pro pacienta.
Reproduction is authorised provided the source is acknowledged. treatment for as long as the doctor believes the patient is benefiting from it.
Reproduction is authorised provided the source is acknowledged. dne, kdy bude mít pacientka dostatek velkých folikulů (váčků ve vaječníku, v nichž jsou uložena vajíčka).
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. do 30 mg, nicméně v závislosti na reakci pacienta může být nutné ji individuálně upravit.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. do krmiva pro prasata sám majitel zvířat a používá ho k léčbě jednotlivých prasat.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. dobu jako první infuze.
Reproduction is authorised provided the source is acknowledged. same time as the first infusion.
Reproduction is authorised provided the source is acknowledged. dokud je přínosná.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. doplněním ve formě samostatného léku, přičemž mezi každým zvýšením dávky by mělo uplynout 7 až 14 dnů.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. dosažena optimální rovnováha mezi úlevou od bolesti a možnými nežádoucími účinky.
Reproduction is authorised provided the source is acknowledged. possible side effects.
Reproduction is authorised provided the source is acknowledged. dostávat 3 mg jednou týdně.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. dvakrát denně, a to obvykle po dobu přesahující jeden měsíc (32 až 38 dní) po náhradě kyčelního kloubu nebo po dobu 10 až 14 dnů po náhradě kolenního kloubu.
Reproduction is authorised provided the source is acknowledged. replacement.
Reproduction is authorised provided the source is acknowledged. dávku 800 mg jednou denně za předpokladu, že jsou dostatečně zdraví a že bylo prokázáno, že virus HIV způsobující infekci není v jejich případě na přípravek Prezista rezistentní.
Reproduction is authorised provided the source is acknowledged. be taken by previously treated patients, provided that the patients are healthy enough and that the HIV virus causing their infection has been shown not to be resistant to Prezista.
Reproduction is authorised provided the source is acknowledged. dávky přípravku Tasmar by měly být podány o přibližně 6 a 12 hodin později.
Reproduction is authorised provided the source is acknowledged. together with the first daily dose of the levodopa preparation, and subsequent doses of Tasmar should be given approximately 6 and 12 hours later.
Reproduction is authorised provided the source is acknowledged. dávkách, třikrát nebo čtyřikrát denně, přičemž každá jednotlivá dávka by neměla přesáhnout 20 mg.
Firdapse is taken in divided doses, three or four times a day, and a single dose should not be more than 20 mg.
Reproduction is authorised provided the source is acknowledged. emtricitabinu či tenofoviru nebo užívali odlišné dávky, budou muset užívat léčivé přípravky obsahující emtricitabin nebo tenofovir disoproxil samostatně.
Reproduction is authorised provided the source is acknowledged. tenofovir, or need to take different doses, they will need to take medicines containing emtricitabine or tenofovir disoproxil separately.
Reproduction is authorised provided the source is acknowledged. enzymů dochází k nižší tvorbě prostaglandinu.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. folikulární lymfom (nádor lymfatické tkáně).
Reproduction is authorised provided the source is acknowledged. follicular lymphoma (a cancer of the lymph tissue).
Reproduction is authorised provided the source is acknowledged. hemodialýzu (metodu čištění krve) a u pacientů starších 75 let je možné použít počáteční dávku 75 mg.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. hladinu atazanaviru v krvi, jelikož zpomaluje jeho odbourávání.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. hladiny neutrofilů (určitého typu bílých krvinek, které bojují s infekcí) a destiček (složek, které napomáhají srážení krve), může být nutné dávku snížit nebo léčbu odložit.
Reproduction is authorised provided the source is acknowledged. that fights infection) and platelets (components that help the blood to clot), the dose may have to be reduced or treatment may have to be delayed.
Reproduction is authorised provided the source is acknowledged. hyperreaktivita bronchů (stav, při němž se dýchací cesty vedoucí do plic snadno zúží).
Reproduction is authorised provided the source is acknowledged. bronchial hyperresponsiveness (a state in which the airways of the lungs narrow easily).
Reproduction is authorised provided the source is acknowledged. hypoglykémie (nízké hladiny cukru v krvi).
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. imunitního systému.
Reproduction is authorised provided the source is acknowledged. system.
Reproduction is authorised provided the source is acknowledged. interleukin-5, která podporuje tvorbu a přežívání eosinofilů.
Reproduction is authorised provided the source is acknowledged. reduces the numbers of eosinophils.
Reproduction is authorised provided the source is acknowledged. invazivní onemocnění (např. meningitida – zánět mozkových blan) vyvolané bakteriemi
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. invazivní onemocnění (např. pneumonie a meningitida – zánět mozkových blan) vyvolané bakterií
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. jak ji snáší.
Reproduction is authorised provided the source is acknowledged. tolerates the treatment.
Reproduction is authorised provided the source is acknowledged. je podat pacientovi dávku radioaktivního jodu, který se ukáže ve tkáni štítné žlázy na skenu.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. je podobný přípravku Elonva, ale je vhodný ke každodennímu injekčnímu podání.
Reproduction is authorised provided the source is acknowledged. medicine similar to Elonva, but suitable for daily injection, may be given.
Reproduction is authorised provided the source is acknowledged. jednu až čtyři hodiny po ukončení operace.
Reproduction is authorised provided the source is acknowledged. after the end of the operation.
Reproduction is authorised provided the source is acknowledged. jedné vysoké síle, zatímco referenční léčivý přípravek je k dispozici ve třech silách – stejně vysoké a dvou nižších.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. jestli trpí cirhózou (zjizvením) jater nebo jeho játra nefungují správně.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. k dispozici postupy pro uchovávání krve nebo jsou nedostatečné, protože chirurgický zákrok vyžaduje velký objem krve.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. k léčbě dospělých s MD/MPD, u kterých došlo k přeskupení genu receptoru pro růstový faktor krevních destiček (PDGFR), pokročilý hyperozinofilní syndrom (HES) nebo chronická eozinofilní leukemie (CEL), což jsou onemocnění, při kterých se růst eozinofilů (jiných typů bílých krvinek) začíná vymykat kontrole.
Glivec is used to treat adults with MD/MPD who have re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR); advanced hypereosinophilic syndrome (HES) or chronic eosinophilic leukaemia (CEL), diseases in which eosinophils (another type of white blood cell) start growing out of control.
Reproduction is authorised provided the source is acknowledged. k léčbě infekcí vyvolaných určitými gastrointestinálními oblými červy (blíže určenými v příbalové informaci) u koček a psů.
Reproduction is authorised provided the source is acknowledged. for the treatment of infections with certain (as specified in the package leaflet) gastrointestinal roundworms in cats and dogs.
Reproduction is authorised provided the source is acknowledged. k léčbě přetrvávající neutropenie u pacientů s pokročilou formou infekce virem lidské imunodeficience (HIV) s cílem omezit riziko bakteriálních infekcí tam, kde nejsou vhodné jiné možnosti léčby neutropenie.
Reproduction is authorised provided the source is acknowledged. to treat persistent neutropenia in patients with advanced human immunodeficiency virus (HIV) infection, to reduce the risk of bacterial infections when other treatments are not appropriate.
Reproduction is authorised provided the source is acknowledged. katarální horečky ovcí, které byly inaktivovány, aby nemohly vyvolat onemocnění.
Reproduction is authorised provided the source is acknowledged. have been inactivated so that they cannot cause the disease.
Reproduction is authorised provided the source is acknowledged. ke snížení nutnosti krevních transfuzí u dospělých se středně závažnou anémií, kteří mají podstoupit větší ortopedickou operaci (operaci kostí), například operaci kyčelního kloubu.
Reproduction is authorised provided the source is acknowledged. to reduce the need for blood transfusions in adults with moderate anaemia who are about to undergo major orthopaedic (bone) surgery, such as hip surgery.
Reproduction is authorised provided the source is acknowledged. kmenových buněk.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. kombinované léčby dvěma přípravky najednou podávanými ústně (kombinovaná léčba třemi přípravky najednou).
Reproduction is authorised provided the source is acknowledged. control is needed.
Reproduction is authorised provided the source is acknowledged. kontaktu s virem katarální horečky ovcí, jejich imunitní systém bude schopen vytvářet protilátky rychleji.
Reproduction is authorised provided the source is acknowledged. exposed to the bluetongue virus, the immune system will be able to produce antibodies more quickly.